Breast Cancer

, Volume 17, Issue 2, pp 80–85 | Cite as

Breast cancer stem cells

  • Kazuharu Kai
  • Yoshimi Arima
  • Toshio Kamiya
  • Hideyuki Saya
Special Feature Breast cancer research from bench to bedside


Since the initial discovery of leukemia stem cells nearly a decade ago, a great deal of cancer research has focused on the identification of cancer stem cells (CSCs) in many types of solid tumors, including breast cancer. Through analysis of cell surface markers and xenotransplant models, a subpopulation of putative human breast cancer stem cells (BCSCs) that is CD24-negative/CD44-positive (CD24/CD44+) and bears high aldehyde dehydrogenase 1 activity has been isolated in clinical samples of breast cancer tissues. Human BCSCs are considered to be derived from basal cells that reside in the basal membranes of alveolar units in human adult mammary glands. Furthermore, BCSCs have been shown to express higher levels of oxidative stress-responsive genes, which could confer part of their ability to resist anti-cancer therapy, than non-CSCs. The emerging picture of the biological properties of BCSCs would contribute for devising innovative therapies for breast cancer, targeting the intrinsic and extrinsic factors that maintain the BCSCs.


Self-renewal Somatic (tissue-specific) stem cell Niche Epithelial to mesenchymal transition (EMT) 


  1. 1.
    Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.CrossRefPubMedGoogle Scholar
  3. 3.
    Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–15.CrossRefPubMedGoogle Scholar
  4. 4.
    Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC. Early breast cancer. Lancet. 2009;373:1463–79.CrossRefPubMedGoogle Scholar
  5. 5.
    Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253–61.CrossRefPubMedGoogle Scholar
  6. 6.
    Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755–68.CrossRefPubMedGoogle Scholar
  7. 7.
    Vaillant F, Asselin-Labat M-L, Shackleton M, Lindeman GJ, Visvader JE. The emerging picture of the mouse mammary stem cell. Stem Cell Rev. 2007;3:114–23.CrossRefPubMedGoogle Scholar
  8. 8.
    Vaillant F, Asselin-Labat M-L, Shackleton M, Forrest NC, Lindeman GJ, Visvader JE. The mammary progenitor marker CD61/β3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res. 2008;68:7711–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996;183:1797–806.CrossRefPubMedGoogle Scholar
  10. 10.
    Hirschmann-Jax C, Foster AE, Wulf GG, Goodell MA, Brenner MK. A distinct “side population” of cells in human tumor cells: implications for tumor biology and therapy. Cell Cycle. 2005;4:203–5.PubMedGoogle Scholar
  11. 11.
    Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD, Sorrentino BP. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci USA. 2002;99:12339–44.CrossRefPubMedGoogle Scholar
  12. 12.
    Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1:555–67.CrossRefPubMedGoogle Scholar
  14. 14.
    Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009;69:1302–13.CrossRefPubMedGoogle Scholar
  15. 15.
    Dick JE. Looking ahead in cancer stem cell research. Nat Biotechnol. 2009;27:44–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459:262–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Werbowetski-Ogilvie TE, Bossé M, Stewart M, Schnerch A, Ramos-Mejia V, Rouleau A, et al. Characterization of human embryonic stem cells with features of neoplastic progression. Nat Biotechnol. 2009;27:91–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Dick JE. Stem cell concepts renew cancer research. Blood. 2008;112:4793–807.CrossRefPubMedGoogle Scholar
  19. 19.
    Smalley M, Ashworth A. Stem cells and breast cancer: a field in transit. Nat Rev Cancer. 2003;3:832–44.CrossRefPubMedGoogle Scholar
  20. 20.
    Nakshatri H, Srour EF, Badve S. Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr Stem Cell Res Ther. 2009;4:50–60.CrossRefPubMedGoogle Scholar
  21. 21.
    Trachootham D, Alexandre J, Huang P: Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009. doi:10.1038/nrd2803.
  22. 22.
    Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458:780–3.CrossRefPubMedGoogle Scholar
  23. 23.
    Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.CrossRefPubMedGoogle Scholar
  24. 24.
    Gilbertson RJ, Rich JN. Making a tumour’s bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer. 2007;7:733–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Shintani Y, Wheelock MJ, Johnson KR. Phosphoinositide-3 kinase-Rac1-c-Jun NH2-terminal kinase signaling mediates collagen I-induced cell scattering and up-regulation of N-cadherin expression in mouse mammary epithelial cells. Mol Biol Cell. 2006;17:2963–75.CrossRefPubMedGoogle Scholar
  26. 26.
    Das B, Tsuchida R, Malkin D, Koren G, Baruchel S, Yeger H. Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells. 2008;26:1818–30.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2009

Authors and Affiliations

  • Kazuharu Kai
    • 1
  • Yoshimi Arima
    • 1
  • Toshio Kamiya
    • 1
  • Hideyuki Saya
    • 1
  1. 1.Division of Gene Regulation, Institute for Advanced Medical ResearchKeio University School of Medicine, Keio UniversityTokyoJapan

Personalised recommendations